MedTrace Logo

Improving Nighttime Access to Care and Treatment; Part 2- Ghana

NCT05506683 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1239

Last updated 2025-09-25

No results posted yet for this study

Summary

Globally, leading causes of death among children one month to 5 years old are pneumonia, diarrheal disease and malaria which are treatable early in the disease-course with low-cost medications. However, these diseases can progress to emergencies when access to care is delayed. In response, a telemedicine and medication delivery service (TMDS) was designed to improve nighttime access to pediatric care and treatment. The TMDS will be implemented in three distinct Ghanaian community to evaluate the clinical safety, operational feasibility of implementing,and scalability of the service.

Conditions

  • Pediatric ALL
  • Acute Disease

Interventions

OTHER

MotoMeds pediatric telemedicine and medication delivery service (TMDS)

The intervention is use of a pediatric TMDS. Eligible children experiencing acute illness are examined over the phone by EMTs who follow a set of clinical guidelines to triage, assess, and develop treatment plans for participants. To evaluate the TMDS and as a safety measure EMTs will also examine most participants in-person a their homes following the phone exam.

Sponsors & Collaborators

  • Ghana National Ambulance Service

    collaborator UNKNOWN

  • University of Florida

    lead OTHER

Principal Investigators

  • Torben K Becker, MD, PhD · University of Florida

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-16
Primary Completion
2025-07-01
Completion
2025-07-01

Countries

  • Ghana

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05506683 on ClinicalTrials.gov